# Bristol-Myers Squibb Company > Clarifo company profile — qualitative business description generated from > the company's filings. Financial statements, charts and ratios are > available on Clarifo (https://www.clarifo.com/en/companies/Bristol-Myers Squibb Company). ## Overview Bristol Myers Squibb is a U.S.-based biopharmaceutical company that discovers, develops, manufactures, markets, and sells innovative medicines for serious diseases. Its portfolio is concentrated in oncology, hematology, immunology, cardiovascular, and neuroscience, with a mix of marketed products and pipeline assets designed to support long-term growth. ## Products & services • Oncology medicines including Opdivo, Yervoy, and Breyanzi • Hematology and blood disorder therapies including Reblozyl and Revlimid • Immunology and inflammation products including Orencia and Zeposia • Cardiovascular medicine Eliquis and heart-failure therapy Camzyos • Neuroscience and specialty medicines, plus radiopharmaceutical assets • R&D, licensing, and commercialization of new biologic and cell therapies - **Oncology** (35%) — Immuno-oncology, combination regimens, and cell-therapy products for solid tumors and blood cancers. - **Cardiovascular** (25%) — Anticoagulation and cardiac medicines, anchored by Eliquis and Camzyos. - **Hematology** (20%) — Therapies for multiple myeloma, anemia, and other blood disorders, including legacy and growth products. - **Immunology** (10%) — Autoimmune and inflammatory disease treatments sold to specialist prescribers and hospitals. - **Other / Alliance Revenue** (10%) — Royalties, alliance-related revenues, and non-core product or licensing income. - Oncology medicines: Opdivo, Yervoy, Breyanzi, and related combinations - Hematology products: Reblozyl, Revlimid, Pomalyst, and Sprycel - Immunology products: Orencia, Zeposia, and emerging autoimmune assets - Cardiovascular products: Eliquis and Camzyos - Radiopharmaceutical and cell-therapy pipeline assets from acquisitions and licensing - Alliance, licensing, and co-commercialization arrangements for pipeline expansion ## Customers BMS sells primarily to wholesalers, distributors, specialty pharmacies, hospitals, clinics, and government agencies, with physician specialists driving much of the end demand. In the U.S., some products are also distributed through REMS-certified pharmacies or direct-to-patient offerings, reflecting tighter control for safety-sensitive medicines. Internationally, the company often relies on distributors that handle logistics, regulatory support, and promotion, which makes channel management and compliance important to execution. - **Wholesalers and distributors** (primary) — Buy large volumes for downstream resale and inventory buffering; critical for U.S. and international channel access. - **Specialty pharmacies** (primary) — Dispense REMS-controlled and specialty medicines such as Revlimid, Pomalyst, and Camzyos. - **Hospitals and clinics** (primary) — Purchase and administer oncology, hematology, and infusion therapies used in specialist care settings. - **Physician specialists** (primary) — Prescribe BMS medicines in oncology, cardiology, immunology, and hematology based on clinical evidence. - **Government and managed care** (secondary) — Influence formulary access, rebates, and reimbursement economics, especially in the U.S. and Europe. - Wholesalers and distributors that stock and resell BMS medicines - Specialty pharmacies for controlled-distribution and specialty products - Hospitals and clinics that administer oncology and specialty therapies - Physician specialists who prescribe branded medicines for serious diseases - Government and managed-care customers influencing access and reimbursement - Patients reached through direct-to-patient or REMS-controlled channels ## Geography BMS reports two main revenue regions: the United States and International markets, with the U.S. representing the largest share and international revenue spread across many countries. The company notes that no single country outside the U.S. contributed more than 10% of total revenue, which reduces concentration but increases exposure to broad pricing, reimbursement, and foreign exchange differences. It also operates globally through distributors and local commercial structures, and it has expanded manufacturing and development capabilities in the U.S., including Indianapolis for radiopharmaceuticals. - **United States** (69.8%) — Based on 2025 six-month revenue: US $16,392m of $23,470m total. - **International** (28.1%) — Includes Puerto Rico; no single non-U.S. country exceeded 10%. - **Other** (2.1%) — Royalties and alliance-related revenues not sold by regional commercial organizations. - United States is the largest revenue region and the main commercial base - International revenue is diversified; no single non-U.S. country exceeds 10% - Puerto Rico is included in the International revenue reporting line - U.S. channel inventory and DSA agreements are important to revenue visibility - Indianapolis radiopharmaceutical facility supports U.S. manufacturing expansion - Foreign exchange affects international revenue growth and comparability ## Strategy BMS is focused on concentrating capital and R&D on transformational medicines in areas where it believes it has a competitive edge, while improving operating efficiency across the enterprise. Recent moves show a strategy of supplementing internal research with licensing, collaborations, and acquisitions to deepen the pipeline in oncology, immunology, and radiopharmaceuticals. The company is also pushing commercial execution in key marketed products while using productivity initiatives to fund growth and shareholder returns. - **Pipeline expansion through BD and partnerships** (short-term) — Offsets patent and generic pressure by adding new assets and indications. - **Commercial execution on core products** (short-term) — Eliquis, Opdivo, Reblozyl, Yervoy, and Orencia remain key revenue and cash drivers. - **Operational productivity and cost savings** (medium-term) — Improves margins and funds R&D and shareholder returns amid pricing pressure. - **Radiopharmaceutical platform build-out** (medium-term) — Creates a differentiated growth platform in precision oncology and diagnostics. - Prioritize transformational medicines in oncology, hematology, immunology, and cardiovascular disease - Use business development to add late-stage and early-stage pipeline assets - Expand radiopharmaceutical capabilities and manufacturing footprint - Drive commercial execution in key marketed products like Eliquis and Opdivo - Capture cost savings through enterprise productivity and operating-model simplification - Allocate capital toward long-term growth and shareholder returns ## Risks BMS faces heavy exposure to pricing pressure, reimbursement changes, and loss of exclusivity on a concentrated set of products that drive most revenue and earnings. Its global footprint also exposes it to foreign exchange, regulatory, channel, and compliance risks, while its increasing use of AI, partnerships, and controlled distribution adds operational complexity. Generic competition, safety/regulatory actions, and cybersecurity remain important industry-wide threats. - **Dependence on key products** [critical] — A majority of revenue and earnings comes from a small set of medicines, so any loss of exclusivity or demand decline can materially hurt results. - **Pricing pressure and reimbursement reform** [high] — U.S. and international pricing restrictions, rebates, and channel changes can compress net selling prices and margins. - **Generic competition and loss of exclusivity** [high] — Generic entrants can rapidly erode sales volumes and pricing for mature products. - **Regulatory and controlled-distribution complexity** [medium] — REMS programs and country-specific distribution rules can limit access and increase operational burden. - **Cybersecurity and IT disruption** [medium] — Business operations depend on digital systems and sensitive data, making outages or breaches potentially costly. - Pricing pressure and rebate changes can reduce revenue and margins - Dependence on a few key products creates concentration risk - Patent expiry and generic erosion can quickly reduce sales - REMS and controlled distribution add compliance and execution risk - Cybersecurity and IT outages can disrupt operations and expose data - AI and third-party systems may create errors, bias, or regulatory issues ## Accounting Revenue recognition is highly judgmental because BMS records sales net of gross-to-net adjustments such as chargebacks, rebates, discounts, and returns. Quarterly results can also be affected by channel inventory movements, Medicare Part D changes, foreign exchange, and the timing of alliance or royalty revenue, so reported growth may differ from underlying demand. Acquisitions, licenses, and collaborations add further accounting complexity through intangible assets, contingent consideration, and potential impairment testing. - **Gross-to-net revenue adjustments** — Can materially change quarterly and annual sales recognition - **Channel inventory and seasonality** — Makes quarterly comparisons less representative of underlying demand - **Alliance and royalty revenue** — Affects mix, growth rates, and comparability across periods - **Acquisition and licensing accounting** — Can affect amortization, balance sheet values, and earnings - Revenue is recorded net of GTN adjustments that rely on estimates - Chargebacks, rebates, and discounts can materially change reported sales - Channel inventory changes can distort quarter-to-quarter comparability - Alliance and royalty revenue may be recognized differently from product sales - Acquisitions and licenses can create intangible assets and impairment risk - Foreign exchange affects reported international revenue growth --- *Last updated: 2026-08-11T04:03:56.228997+00:00*